SciSparc Secures Israeli Patent Enhancing Opioid Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Newsfilter
- Patent Grant: SciSparc's majority-owned NeuroThera has secured a patent in Israel for its proprietary combination of opioids and N-acylethanolamines, further strengthening its global intellectual property protection and enhancing its competitive position in the central nervous system disorder treatment market.
- Efficacy Enhancement: This patented technology enhances opioid analgesia through N-acylethanolamines, with studies indicating it can reduce side effects like tolerance and dependence while maintaining pain relief, addressing the urgent market need for safer solutions.
- Market Potential: According to market research, the global opioid market is projected to reach $5.5 to $5.7 billion in 2024, and NeuroThera's innovative combination could capture significant market share while mitigating issues of opioid misuse and addiction.
- Strategic Importance: NeuroThera CEO Oz Adler highlighted that the patent represents a crucial achievement in maintaining strong pain relief without compromising patient safety, potentially providing robust support for the company's future drug development and market initiatives.
SPRC
$1.31+Infinity%1D
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
